Suzhou Ribobio Biotechnology Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
453
- Stock Symbol
-
06938
- Investments
-
2
- Share Price
-
$5.16
- (As of Friday Closing)
Suzhou Ribobio Biotechnology General Information
Description
Suzhou Ribo Life Science Co Ltd is a biopharmaceutical company engaged in oligonucleotide R&D, with a focus on siRNA therapeutics. The company's pipeline focuses on cardiovascular, metabolic, renal and liver diseases. Its pipeline includes RBD4059, RBD5044, RBD7007, RBD1119, RBD3103, SR122, SR126, RBD1016, SR112/SR113, among others. It has one reportable operating segment.
Contact Information
Website
www.ribolia.comCorporate Office
- Number 168 Yuanfeng Road, Yushan Town
- Kunshan, Jiangsu 215300
- China
Corporate Office
- Number 168 Yuanfeng Road, Yushan Town
- Kunshan, Jiangsu 215300
- China
Suzhou Ribobio Biotechnology Timeline
Suzhou Ribobio Biotechnology Stock Performance
As of 20-Nov-2026, Suzhou Ribobio Biotechnology’s stock price is $5.16. Its current market cap is $873M with 169M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.16 | $5.10 | $4.72 - $12.29 | $873M | 169M | 357K | -$0.15 |
Suzhou Ribobio Biotechnology Financials Summary
As of 30-Jun-2026, Suzhou Ribobio Biotechnology has a trailing 12-month revenue of $66.4M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,057,618 | |||
| Revenue | 66,373 | 20,651 | 19,877 | 6 |
| EBITDA | (7,708) | (30,226) | (26,580) | (52,536) |
| Net Income | (24,243) | (38,666) | (37,649) | (60,545) |
| Total Assets | 414,868 | 120,029 | 89,157 | 101,042 |
| Total Debt | 79,885 | 78,618 | 58,750 | 58,508 |
Suzhou Ribobio Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Suzhou Ribobio Biotechnology Comparisons
Industry
Financing
Details
Suzhou Ribobio Biotechnology Competitors (43)
One of Suzhou Ribobio Biotechnology’s 43 competitors is Sirnaomics, a Formerly VC-backed company based in Gaithersburg, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sirnaomics | Formerly VC-backed | Gaithersburg, MD | ||||
| WaVe Life Sciences | Formerly VC-backed | Cambridge, MA | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Apeptico | Formerly VC-backed | Vienna, Austria | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland |
Suzhou Ribobio Biotechnology Patents
Suzhou Ribobio Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026233343-A1 | Oligonucleotides, oligonucleotide conjugates, compositions, and uses | Pending | 07-May-2025 | ||
| WO-2026228826-A1 | Oligonucleotide, oligonucleotide conjugate, and composition and use | Pending | 30-Apr-2025 | ||
| WO-2026228824-A1 | Oligonucleotide, oligonucleotide conjugate, composition and use | Pending | 30-Apr-2025 | ||
| WO-2026184535-A1 | Oligonucleotide, oligonucleotide conjugate, composition, and use | Pending | 03-Mar-2025 | ||
| WO-2026139046-A1 | Oligonucleotide, oligonucleotide conjugate, composition, and use thereof | Pending | 26-Dec-2024 |
Suzhou Ribobio Biotechnology Signals
Suzhou Ribobio Biotechnology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Suzhou Ribobio Biotechnology Investments (2)
Suzhou Ribobio Biotechnology’s most recent deal was a Later Stage VC with Azemidite for . The deal was made on 02-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Azemidite | 02-Jul-2026 | Later Stage VC | Specialty Chemicals | ||
| Kunshan RiboQuark Pharmaceutical Technology | 01-Sep-2012 | Joint Venture | Drug Discovery |
Suzhou Ribobio Biotechnology ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Suzhou Ribobio Biotechnology FAQs
-
When was Suzhou Ribobio Biotechnology founded?
Suzhou Ribobio Biotechnology was founded in 2007.
-
Where is Suzhou Ribobio Biotechnology headquartered?
Suzhou Ribobio Biotechnology is headquartered in Kunshan, China.
-
What is the size of Suzhou Ribobio Biotechnology?
Suzhou Ribobio Biotechnology has 453 total employees.
-
What industry is Suzhou Ribobio Biotechnology in?
Suzhou Ribobio Biotechnology’s primary industry is Drug Discovery.
-
Is Suzhou Ribobio Biotechnology a private or public company?
Suzhou Ribobio Biotechnology is a Public company.
-
What is Suzhou Ribobio Biotechnology’s stock symbol?
The ticker symbol for Suzhou Ribobio Biotechnology is 06938.
-
What is the current stock price of Suzhou Ribobio Biotechnology?
As of 20-Nov-2026 the stock price of Suzhou Ribobio Biotechnology is $5.16.
-
What is the current market cap of Suzhou Ribobio Biotechnology?
The current market capitalization of Suzhou Ribobio Biotechnology is $873M.
-
What is Suzhou Ribobio Biotechnology’s current revenue?
The trailing twelve month revenue for Suzhou Ribobio Biotechnology is $66.4M.
-
Who are Suzhou Ribobio Biotechnology’s competitors?
Sirnaomics, WaVe Life Sciences, Intellia Therapeutics, Apeptico, and CRISPR Therapeutics are some of the 43 competitors of Suzhou Ribobio Biotechnology.
-
What is Suzhou Ribobio Biotechnology’s annual earnings per share (EPS)?
Suzhou Ribobio Biotechnology’s EPS for 12 months was -$0.15.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process